Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han rats

Authors

  • Francisco Sacadura Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, 4585-116 Gandra, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Forensic Science Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal; LAQV/REQUIMTE, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072, Porto, Portugal
  • Cláudia Marques CHRC, NOVA Medical School, NOVA University Lisbon, Lisbon, Portugal
  • Andreia Machado Brito-da-Costa Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, 4585-116 Gandra, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Forensic Science Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal; LAQV/REQUIMTE, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072, Porto, Portugal; Associate Laboratory i4HB - Institute for Health and Bioeconomy, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
  • Mariana Carvalho Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, 4585-116 Gandra, Portugal; LAQV/REQUIMTE, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072, Porto, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Translational Toxicology Research Laboratory, University
  • Helena Carmo Associate Laboratory i4HB - Institute for Health and Bioeconomy, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
  • Ricardo Jorge Dinis-Oliveira Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, 4585-116 Gandra, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Translational Toxicology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal; Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, Porto, Portugal
  • Áurea Madureira-Carvalho Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, 4585-116 Gandra, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Forensic Science Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal https://orcid.org/0000-0002-7569-6802
  • Diana Dias da Silva Associate Laboratory i4HB - Institute for Health and Bioeconomy, University Institute of Health Sciences - CESPU, 4585-116 Gandra, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Forensic Science Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal; LAQV/REQUIMTE, ESS, Polytechnic of Porto, Rua Dr. António Bernardino de Almeida, 400, 4200-072, Porto, Portugal; Associate Laboratory i4HB - Institute for Health and Bioeconomy, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; UCIBIO – Research Unit on Applied Molecular Biosciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal

DOI:

https://doi.org/10.48797/sl.2026.492

Keywords:

Poster

Abstract

Background: Psilocybin, the main psychoactive compound found in Psilocybe mushrooms, has gained increasing attention due to its potential therapeutic effects in neuropsychiatric disorders [1]. Beyond its central effects, increasing evidence highlights the relevance of the gut–brain axis, suggesting that psychedelics may also influence intestinal microbiota composition. Whole mushroom extracts contain additional bioactive compounds that may modulate these effects, yet comparative preclinical data between pure psilocybin and mushroom extracts remain limited [2,3]. Objective: To evaluate the impact of pure psilocybin and Psilocybe cubensis extract on gut microbiota in vivo. Methods: Eighteen male Wistar Han rats (250–275 g; 8–9 weeks old) were randomly assigned to three groups (n=6): control (0.9% NaCl), psilocybin (3 mg·kg⁻¹), and P. cubensis extract (equivalent to 3 mg·kg⁻¹ psilocybin/psilocin). Treatments were administered by oral gavage (0.5 mL·kg⁻¹). Fecal samples were collected at baseline (T1) and at days 7 (T7) and 14 (T14) post-exposure for microbiota analysis. Microbial profiling was performed using long-read amplicon sequencing targeting the full-length 16S rRNA gene. Libraries were prepared using SMRTbell technology and sequenced on the PacBio platform. Bioinformatic analysis enabled high-resolution taxonomic assignment and reconstruction of microbial community structure, improving species-level identification accuracy. Statistical analysis included ANOVA and multivariate analysis of beta-diversity (p<0.05). All procedures were approved by the institutional Animal Welfare Committee and DGAV, in accordance with European and national legislation. Results: Baseline microbiota composition (T1) was similar across all groups, clustering closely together, as expected prior to treatment. This profile remained comparable to the control group at T7 and T14. In contrast, distinct shifts in microbial community structure were observed in treated groups. Both psilocybin and P. cubensis extract induced separation from baseline and control profiles at T7, with further divergence at T14. This effect was more pronounced in the psilocybin group, which exhibited the greatest distance in cluster analysis, indicating a stronger impact on microbiota composition. Conclusions: These findings suggest a time-dependent modulation of gut microbiota induced by both treatments, with differential magnitude between the pure compound and the whole extract.

References

1. Erkizia-Santamaría, I. et al. Role of endogenous serotonin in psychedelic-like effects of psilocybin in mice. Int J Neuropsychopharmacol 2025, 28(6), pyaf035, doi:10.1093/ijnp/pyaf035.

2. Ali, A. et al. Natural vs. synthetic psilocybin: The same or completely different? In Mushrooms with Therapeutic Potentials: Recent Advances in Research and Development; Springer Nature: Singapore, 2023; pp. 479–492, doi:10.1007/978-981-19-9550-7_18.

3. Johnson-Groh, M. Addressing a critical knowledge gap in psychedelic research. ACS Cent Sci 2025, 11(8), 1256–126.

Downloads

Published

2026-05-05

How to Cite

Sacadura, F., Marques, C., Brito-da-Costa, A. M., Carvalho, M., Carmo, H., Dinis-Oliveira, R. J., Madureira-Carvalho, Áurea, & Dias da Silva, D. (2026). Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han rats. Scientific Letters, 1(Sup 1). https://doi.org/10.48797/sl.2026.492

Issue

Section

Posters

Most read articles by the same author(s)

1 2 3 4 5 6 > >> 

Similar Articles

<< < 5 6 7 8 9 10 11 12 13 14 > >> 

You may also start an advanced similarity search for this article.